Three times a day, 68 adults in an opioid-use-disorder study received a question on their phones: how aware were they of sensations inside their bodies? Their answers helped researchers at the University of California San Diego explore why mindfulness therapy paired with ketamine might ease opioid cravings.
The study, published Nov. 5, 2026, in the Journal of Psychopharmacology, examined a possible link between body awareness and recovery. Opioid use disorder can disrupt a person’s ability to notice and interpret signals such as changes in breathing, heartbeat or muscle tension. These signals, known as interoception, can help people understand how they feel and respond to distress. The researchers wanted to learn whether ketamine could strengthen this skill when added to a mindfulness-based treatment.
The work builds on a randomized clinical trial published in Nature Mental Health in March 2026. All 68 adults in that trial were taking buprenorphine, a medication used to treat opioid use disorder. They were assigned to receive either Mindfulness-Oriented Recovery Enhancement, or MORE, alone, or MORE combined with two sessions of ketamine-assisted psychotherapy.
MORE is an eight-week therapy developed by senior study author Eric Garland, a professor of psychiatry at UC San Diego School of Medicine. It combines mindfulness with ways to rethink stressful experiences and take in positive feelings. Earlier clinical trials found that MORE reduced opioid misuse by 45% and, for people receiving medication for opioid use disorder, reduced drug relapse by 42%.
In the earlier trial, people who received MORE with ketamine reported less drug use after treatment and lower opioid cravings at a three-month follow-up than those who received MORE alone. From the end of treatment through that follow-up, the ketamine group had 44% fewer instances of drug use. The new analysis looked for a possible explanation for those results.
Participants received smartphone prompts three times a day during treatment and for one month afterward. Body awareness rose more quickly among those receiving ketamine with MORE, with the increase emerging around the time of their first ketamine session. The gains were still present at the one-month follow-up. The researchers also found improvements in two related skills: listening to the body for useful information and using physical sensations to manage distress.
Those improvements were associated with lower opioid cravings three months later. That link does not prove that greater body awareness caused cravings to fall, but it points to one way the combined treatment may help. Garland said addiction can make it hard to recognize what is happening inside the body and respond in ways that support recovery. “Craving isn’t just a thought; it can be experienced throughout the body,” he said.
The findings offer a possible clue for improving addiction care, not a reason to treat ketamine as a stand-alone cure. The study tested ketamine as part of structured therapy among adults already taking buprenorphine. Further research can help clarify how changes in body awareness relate to cravings and whether this approach can support more people in recovery.
